NMUR2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2632647	0.84	17/20
SCHEMBL2625064	0.64	17/20
SCHEMBL2633390	0.60	17/20
SCHEMBL2625082	0.59	17/20
SCHEMBL2628471	0.57	17/20
SCHEMBL2628468	0.53	17/20
SCHEMBL2632769	0.73	16/20
SCHEMBL2628463	0.63	16/20
SCHEMBL2628467	0.55	16/20
SCHEMBL2628462	0.53	16/20
SCHEMBL2632668	0.73	15/20
SCHEMBL5498560	0.65	15/20
SCHEMBL2625080	0.55	15/20
SCHEMBL2628478	0.49	15/20
SCHEMBL2628482	0.56	14/20
SCHEMBL2628464	0.54	14/20
SCHEMBL2625090	0.53	14/20
SCHEMBL3539226	0.71	13/20
SCHEMBL2632729	0.67	13/20
SCHEMBL2625075	0.53	13/20

Clinical trials — most relevant to NMUR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls	PHASE4	COMPLETED
Intravenous Ketorolac and Metoclopramide for Pediatric Migraine in the Emergency Department	PHASE4	COMPLETED
Interaction Between Magnesium and Neostigmine or Sugammadex for the Reversal of a Rocuronium-induced Neuromuscular Block	PHASE4	COMPLETED
OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER	PHASE3	UNKNOWN
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis	PHASE2	UNKNOWN
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor	PHASE1	COMPLETED
Neuroimmune Effects of Opioid Administration	PHASE1	COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
Selective Activation of the Adrenomedullin Receptors in Migraine	nan	NOT_YET_RECRUITING
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
Reversal of Neuromuscular Blockade in Thoracic Surgical Patients	nan	COMPLETED
Chronic Electrical Stimulation to Reduce Bladder Hyperreflexia	nan	COMPLETED
Changes of microRNA Expression in Obstructive and Neurogenic Bladder Dysfunction	nan	COMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments	nan	RECRUITING
Urinary NGF as A Biomarker for Acute Bacterial Cystitis	nan	COMPLETED
Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia	nan	COMPLETED
Association of Urine BDNF and NGF With Lower Urinary System Parameters	nan	RECRUITING
mGluR5 Imaging in ALS Using PET	nan	UNKNOWN
Investigation of Brain Mechanisms Involved in the Urinary Continence Mechanism Associated With Aging	nan	COMPLETED
Exploring the Genetics of Neuropathic Pain	nan	RECRUITING
The Role of Urinary ATP in the Diagnosis, Treatment, and Follow-up of Children With Overactive Bladder	nan	COMPLETED
BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies	nan	COMPLETED
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)	nan	COMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy	nan	COMPLETED
Stimulation-evoked Calcitonin Gene-Related Peptide (CGRP) as Biomarker of Migraine	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a NMUR2 binder may also engage these)

Protein	Name	Similarity
Q8BZ39	—	1.000	Q8BZ39 →
Q58CW4	—	1.000	Q58CW4 →
Q9ESQ4	—	0.997	Q9ESQ4 →
O55040	—	0.992	O55040 →
O88319	—	0.987	O88319 →
Q9JJI5	—	0.987	Q9JJI5 →
P20789	—	0.986	P20789 →
GPR39	G-protein coupled receptor 39	0.985	landscape →
O54798	—	0.983	O54798 →
Q5U431	—	0.983	Q5U431 →
Q8K418	—	0.983	Q8K418 →
P50129	—	0.982	P50129 →
Q8ITC7	—	0.982	Q8ITC7 →
P54833	—	0.982	P54833 →
Q28997	—	0.982	Q28997 →
B4XF06	—	0.982	B4XF06 →
NTSR1	Neurotensin receptor type 1	0.981	landscape →
P35371	—	0.981	P35371 →
Q5IS72	—	0.981	Q5IS72 →
Q75Z89	—	0.981	Q75Z89 →
O46635	—	0.980	O46635 →
P97292	—	0.980	P97292 →
Q61121	—	0.978	Q61121 →
P14842	—	0.978	P14842 →
Q5R4Q6	—	0.978	Q5R4Q6 →
HTR2A	5-hydroxytryptamine receptor 2A	0.978	landscape →
P52703	—	0.978	P52703 →
F1R332	—	0.978	F1R332 →
P35363	—	0.978	P35363 →
P50128	—	0.978	P50128 →